ReviewFrontiers of medicine2012
MicroRNAs and lung cancers: from pathogenesis to clinical implications.
Review in Frontiers of medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- Diagnostic value of circulating microRNAs for lung cancer: a meta-analysis.Genetic testing and molecular biomarkers · 2013Pooled it
- Current Evidence Supporting the Role of miRNA as a Biomarker for Lung Cancer Diagnosis Through Exhaled Breath Condensate Collection: A Narrative Review.Life (Basel, Switzerland) · 2025Review
- MiRNAs in Lung Cancer: Diagnostic, Prognostic, and Therapeutic Potential.Diagnostics (Basel, Switzerland) · 2022Review
- Comprehensive Profiling of Genomic and Transcriptomic Differences between Risk Groups of Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.Journal of personalized medicine · 2021Article
- Construction of Potential Gene Expression and Regulation Networks in Prostate Cancer Using Bioinformatics Tools.Oxidative medicine and cellular longevity · 2021Article
- Identification of gene and microRNA changes in response to smoking in human airway epithelium by bioinformatics analyses.Medicine · 2019Article
- Article
- Nucleic Acid-Based Therapeutics for Pulmonary Diseases.AAPS PharmSciTech · 2018Review
- MicroRNA-383-5p acts as a prognostic marker and inhibitor of cell proliferation in lung adenocarcinoma by cancerous inhibitor of protein phosphatase 2A.Oncology letters · 2017Article
- MicroRNA-34a/EGFR axis plays pivotal roles in lung tumorigenesis.Oncogenesis · 2017Article
- MiR-146a-5p inhibits cell proliferation and cell cycle progression in NSCLC cell lines by targeting CCND1 and CCND2.Oncotarget · 2016Article
- miR-19a/b modulates lung cancer cells metastasis through suppression of MXD1 expression.Oncology letters · 2016Article
- MiR-374a suppresses lung adenocarcinoma cell proliferation and invasion by targeting TGFA gene expression.Carcinogenesis · 2016Article
- A double-negative feedback loop between E2F3b and miR- 200b regulates docetaxel chemosensitivity of human lung adenocarcinoma cells.Oncotarget · 2016Article
- miRNAs and resistance to EGFR-TKIs in EGFR-mutant non-small cell lung cancer: beyond 'traditional mechanisms' of resistance.Ecancermedicalscience · 2015Article
- MicroRNA-299-3p promotes the sensibility of lung cancer to doxorubicin through directly targeting ABCE1.International journal of clinical and experimental pathology · 2015Article
- Pulmonary adenocarcinoma: implications of the recent advances in molecular biology, treatment and the IASLC/ATS/ERS classification.Journal of thoracic disease · 2014Review
- MiR-224 promotes the chemoresistance of human lung adenocarcinoma cells to cisplatin via regulating G₁/S transition and apoptosis by targeting p21(WAF1/CIP1).British journal of cancer · 2014Article
- Non-coding RNAs in lung cancer.Oncoscience · 2014Review
- The potential clinical applications and prospects of microRNAs in lung cancer.OncoTargets and therapy · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Lung cancer is the leading cause of cancer-related deaths in the US and worldwide. Better understanding of the disease is warranted for improvement in clinical management. Here we summarize the functions of small-RNA-based, posttranscriptional gene regulators, i.e. microRNAs, in the pathogenesis of lung cancers. We discuss the microRNAs that play oncogenic as well as tumor suppressive roles. We also touch on the value of microRNAs as markers for diagnosis, prognosis and the promising field of microRNA-based novel therapies for lung cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.